WO2012111027A2 - Procédé d'obtention de pemetrexed disodique - Google Patents

Procédé d'obtention de pemetrexed disodique Download PDF

Info

Publication number
WO2012111027A2
WO2012111027A2 PCT/IN2012/000103 IN2012000103W WO2012111027A2 WO 2012111027 A2 WO2012111027 A2 WO 2012111027A2 IN 2012000103 W IN2012000103 W IN 2012000103W WO 2012111027 A2 WO2012111027 A2 WO 2012111027A2
Authority
WO
WIPO (PCT)
Prior art keywords
acid
ethyl
pemetrexed disodium
oxo
pyrimidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2012/000103
Other languages
English (en)
Other versions
WO2012111027A3 (fr
Inventor
Bandi Parthasaradhi Reddy
Kura Rathnakar Reddy
Dasari Muralidhara Reddy
Puranik Ramachandra
Bandi Vamsi Krishna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hetero Research Foundation
Original Assignee
Hetero Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hetero Research Foundation filed Critical Hetero Research Foundation
Priority to EP12747282.7A priority Critical patent/EP2675808A4/fr
Publication of WO2012111027A2 publication Critical patent/WO2012111027A2/fr
Publication of WO2012111027A3 publication Critical patent/WO2012111027A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention provides a process for the preparation of N-[4-[2-(2- amino-4,7-dihydro-4-oxo-lH-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid dimethyl ester or salts thereof.
  • the present invention also provides a process for the preparation of pemetrexed disodium substantially free of enatiomeric impurity.
  • Pemetrexed is chemically, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-lH-pyiTolo[2,3- d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid.
  • Pemetrexed is represented by the following structure:
  • Pemetrexed is an anti-neoplastic agent that exerts its action by disrupting folate- dependent metabolic processes essential for cell replication. It is believed to work by inhibiting three enzymes that are required in purine and pyrimidine biosynthesis- thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide fonnyl transferase (GARFT).
  • TS purine and pyrimidine biosynthesis- thymidylate synthase
  • DHFR dihydrofolate reductase
  • GARFT glycinamide ribonucleotide fonnyl transferase
  • Pemetrexed is available in the market under the brand name ALIMTA ® and marketed by Eli Lilly.
  • pemetrexed disodium crystalline hydrate form I can be prepared by stirring a solution of 4-(2-(2-amino-4(lH)- oxo-4,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl]ethyl]benzoyl-L-glutamic acid diethyl ester in sodium hydroxide and water, pH of the reaction mass was adjusted to 7.7, heated to 60 to 70°C and then added ethanol, and isolating.
  • 4- methylbenzenesulfonic acid can be prepared by reacting 4-[2-(2-amino-4,7-dihydro-4- oxo-lH-pyrrolo[2,3-d]pyiimidin-5-yl)ethyl]benzoic acid with 2-chloro-4,6-dimethoxy- 1,3,5-triazine and L-glutamic acid diethyl ester hydrochloride in the presence of dimethylformamide and N-methylmorpoline at 25°C to obtain a solid. The obtained solid was reacted with p-toluenesulfonic acid in ethanol and then added dimethyl sulfoxide, heating to 80°C, cooling and iso
  • U.S. patent no. 7,138,521 disclosed pemetrexed disodium heptahydrate crystal form.
  • pemetrexed disodium heptahydrate crystal form can be prepared by crystallizing pemetrexed disodium from a solution of pemetrexed disodium in water and acetone.
  • N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo-[2,3,d]-pyrimidin-5- yl)ethyl]benzoyl]-D-glutamic acid disodium salt is enatiomeric impurity of pemetrexed disodium.
  • the chemical formula of enatiomeric impurity may be represented as:
  • the present invention is intended to enhance the purity of pemetrexed disodium.
  • the present invention is directed to reduce or remove enantiomeric impurity from pemetrexed disodium.
  • one object of the present invention is to provide a process for the preparation of N-[4-[2-(2-amino-4,7-dihydro-4-oxo- 1 H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid dimethyl ester or salts thereof.
  • Another object of the present invention is to provide a novel process for the preparation of pemetrexed disodium substantially free of enantiomeric impurity.
  • the present invention provides a process for the preparation of substantially pure compound of formula I or salts thereof,
  • R' is independently a lower alkyl.
  • the present invention provides a process for the preparation of pemetrexed disodium substantially free of enantiomeric impurity, which comprises: a) stirring a solution of N-[4-[2-(2-amino-4,7-dihydro-4-oxo-lH-pyrrolo[2,3- d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid dimethyl ester 4- methylbenzenesulfonic acid with a mixture of sodium hydroxide and water at below 30°C;
  • step (b) adding an organic solvent to the solution obtained in step (b) at below 30°C; and d) isolating the pemetrexed disodium substantially free of enantiomeric impurity.
  • R' is independently a lower alkyl.
  • lower alkyl refers to Ci - C 4 alkyl such as methyl, ethyl, propyl and butyl, and preferable alkyl is methyl or ethyl. More preferable alkyl is methyl.
  • the reaction may preferably be carried out in a solvent system comprising a solvent or mixture of solvents selected from dimethylformamide, dimethyl sulfoxide, methylene chloride, N-methylpyrrolidone and dimethylformamide, and more preferably the solvents are dimethylformamide, dimethyl sulfoxide, N-methylpyrrolidone and methylene chloride.
  • a process for the preparation of pemetrexed disodium substantially free of enantiomeric impurity which comprises:
  • step (b) adding an organic solvent to the solution obtained in step (b) at below 30°C; and d) isolating the pemetrexed disodium substantially free of enantiomeric impurity.
  • pemetrexed disodium substantially free of enantiomeric impurity refers to pemetrexed disodium having the content of enantiomeric impurity in equal to or less than about 0.3% by weight, preferably equal to or less than about 0.2% by weight and more preferably equal to or less than about 0.1% by weight.
  • the contents of pemetrexed disodium and the enantiomeric impurity are determined by High performance liquid chromatography (HPLC).
  • reaction in step (a) may be carried out at below 25°C.
  • the pH of the reaction mass in step (b) may be adjusted to above 7.5.
  • the acid used in step (b) may be a mineral acid or an organic acid and more preferably the acid is mineral acid selected from hydrochloric acid, sulfuric acid or phosphoric acid. Still more preferably the acid is hydrochloric acid.
  • the organic solvent used in step (c) may preferably be a solvent or mixture of solvents selected from the group consisting of methanol, ethanol, isopropanol, isobutanol, n-butanol, acetone, methyl ethyl ketone, methyl isobutyl ketone and diethyl ketone, and more preferably the organic solvents are methanol, ethanol, isopropanol and acetone.
  • reaction in step (c) may be carried out at below 25°C.
  • Isolation of pemetrexed disodium in step (d) can be performed by conventional methods such as cooling, removal of solvents, concentrating the reaction mass, adding an anti-solvent, extraction with a solvent and the like.
  • Step-I Preparation of 4-(4-hydroxy-l-butynyl)benzoic acid methyl ester .
  • Step-Ill Preparation of 4-(4-oxobutyl)benzoic acid methyl ester
  • Step-IV Preparation of 4-(3-bromo-4-oxobutyl)benzoic acid methyl ester
  • Step-V Preparation of 4-[2-(2-amino-4, 7-dihydro-4-oxo-lH-pyrrolo[2,3-d]pyrimidin-5- yl) ethyl] benzoic acid methyl ester
  • Step-VI Preparation of 4-[2-(2-amino-4 -dihydro-4-oxo-lH-pyrrolo[2,3-d]pyrimidin- 5-yl)ethyl] benzoic acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne un procédé de préparation d'ester diméthylique d'acide N-[4-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)- éthyl]benzoyl]-L-glutamique ou de ses sels. La présente invention concerne également un procédé de préparation de pemetrexed disodique essentiellement dépourvu d'impureté énantiomère.
PCT/IN2012/000103 2011-02-15 2012-02-14 Procédé d'obtention de pemetrexed disodique Ceased WO2012111027A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12747282.7A EP2675808A4 (fr) 2011-02-15 2012-02-14 Procédé d'obtention de pemetrexed disodique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN434/CHE/2011 2011-02-15
IN434CH2011 2011-02-15

Publications (2)

Publication Number Publication Date
WO2012111027A2 true WO2012111027A2 (fr) 2012-08-23
WO2012111027A3 WO2012111027A3 (fr) 2012-10-11

Family

ID=46672998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000103 Ceased WO2012111027A2 (fr) 2011-02-15 2012-02-14 Procédé d'obtention de pemetrexed disodique

Country Status (2)

Country Link
EP (1) EP2675808A4 (fr)
WO (1) WO2012111027A2 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150027986A (ko) * 2013-09-05 2015-03-13 주식회사 삼양바이오팜 고순도 페메트렉세드 제조를 위한 향상된 중간체 제조 방법 및 이를 사용하여 고순도 페메트렉세드를 제조하는 방법
CN107628947A (zh) * 2017-09-14 2018-01-26 浙江工业大学 一种培美曲塞二钠关键中间体的制备方法
CN110031567A (zh) * 2019-05-15 2019-07-19 南京制药厂有限公司 培美曲塞二钠中间体二乙酯的分析方法
WO2019244965A1 (fr) * 2018-06-20 2019-12-26 日本化薬株式会社 Préparation pour solution injectable de pémétrexed sodique et son procédé de fabrication
CN111333658A (zh) * 2020-05-06 2020-06-26 贵州联科中贝制药科技有限公司 一种培美曲塞二钠水合物的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0530537B1 (fr) * 1991-08-12 1997-01-08 Takeda Chemical Industries, Ltd. Dérivés de la pyrimidine condensés, leur préparation et leur utilisation comme agents antitumoraux
AU740087B2 (en) * 1997-09-26 2001-11-01 Eli Lilly And Company Processes and intermediates useful to make antifolates
WO2001014379A2 (fr) * 1999-08-23 2001-03-01 Eli Lilly And Company Nouvelle forme cristalline de disodium n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]-pyrimidin-5-yl)ethyl]benzoyl]-l- sel d'acide glutamique et procedes de preparation
CN101417998B (zh) * 2007-10-24 2012-10-24 重庆医药工业研究院有限责任公司 一种培美曲塞盐的纯化方法
CN101591247B (zh) * 2008-05-30 2012-09-05 上海希迪制药有限公司 合成4-(4-甲酯基苯基)丁醛的方法
WO2010030598A2 (fr) * 2008-09-11 2010-03-18 Dr. Reddy's Laboratories Limited Formulations pharmaceutiques comprenant du pemetrexed
TW201118098A (en) * 2009-08-13 2011-06-01 Reddy S Lab Liimited Dr Processes for preparing pemetrexed

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2675808A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150027986A (ko) * 2013-09-05 2015-03-13 주식회사 삼양바이오팜 고순도 페메트렉세드 제조를 위한 향상된 중간체 제조 방법 및 이를 사용하여 고순도 페메트렉세드를 제조하는 방법
KR101578093B1 (ko) 2013-09-05 2015-12-16 주식회사 삼양바이오팜 고순도 페메트렉세드 제조를 위한 향상된 중간체 제조 방법 및 이를 사용하여 고순도 페메트렉세드를 제조하는 방법
CN107628947A (zh) * 2017-09-14 2018-01-26 浙江工业大学 一种培美曲塞二钠关键中间体的制备方法
WO2019244965A1 (fr) * 2018-06-20 2019-12-26 日本化薬株式会社 Préparation pour solution injectable de pémétrexed sodique et son procédé de fabrication
CN110031567A (zh) * 2019-05-15 2019-07-19 南京制药厂有限公司 培美曲塞二钠中间体二乙酯的分析方法
CN111333658A (zh) * 2020-05-06 2020-06-26 贵州联科中贝制药科技有限公司 一种培美曲塞二钠水合物的制备方法

Also Published As

Publication number Publication date
EP2675808A2 (fr) 2013-12-25
WO2012111027A3 (fr) 2012-10-11
EP2675808A4 (fr) 2014-07-09

Similar Documents

Publication Publication Date Title
US9156841B2 (en) Crystalline forms of pemetrexed diacid and processes for the preparation thereof
US20130165654A1 (en) Processes for preparing pemetrexed
US9562050B2 (en) Crystalline forms of pemetrexed diacid and processes for the preparation thereof
EP2675808A2 (fr) Procédé d'obtention de pemetrexed disodique
WO2014195978A2 (fr) Procédé pour la préparation de (3r,4r)-4-méthyl-3-(méthyl-7h-pyrrolo[2,3-d]pyrimidine-4-yl-amino)-ss-oxo-1-pipéridine-propanenitrile et de ses sels
WO2007059905A2 (fr) Nouvelle utilisation de thiénopyrimidines
NZ336124A (en) 5-aralkyl or (aryl, heteroaryl or heteroarylalkyl) substituted pyrrolo[3,4-d]pyrimidinone derivatives and medicaments
US20110124861A1 (en) Process for Preparing Pemetrexed Disodium and Its Intermediate, 4-(4-Carbomethoxyphenyl) Butanal
CN101085775A (zh) 培美曲塞中间体及制备方法
US20110196154A1 (en) Amorphous pemetrexed disodium
KR101101443B1 (ko) 페메트렉세드의 중간체의 제조 방법
JP2016531925A (ja) ペメトレキセド製造のための中間体製造方法及びこれを用いて高純度ペメトレキセドを製造する方法
US9150547B2 (en) Process for the preparation of pazopanib using novel intermediate
CA2827455A1 (fr) Procede pour la production d'un sel de pemetrexed
US8097723B2 (en) Process for the preparation of abacavir
US9604990B2 (en) Crystalline forms of pemetrexed diacid and manufacturing processes therefor
US20060149055A1 (en) Process for the manufacture of cefpodoxime proxetil
EP1590353B1 (fr) Procede pour preparer du cefpodoxime proxetil
US20120245349A1 (en) Process for the production of a pemetrexed salt
KR101372788B1 (ko) 고순도의 페메트렉시드 이나트륨 염의 제조방법
CN119899173A (zh) 一种色瑞替尼基因毒性杂质亚硝基色瑞替尼的制备方法
WO2013100872A1 (fr) Procédé monotope de préparation de pemetrexed disodium

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12747282

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2012747282

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: DE